Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

4.95EUR
14 Jun 2019
Change (% chg)

-- (--)
Prev Close
€4.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
73,621
52-wk High
€5.38
52-wk Low
€3.10

Latest Key Developments (Source: Significant Developments)

AB Science: Positive Recommendation Of IDMC Following Interim Analysis Of Study AB12005
Wednesday, 12 Jun 2019 02:00pm EDT 

June 13 (Reuters) - AB SCIENCE SA ::ANNOUNCED ON WEDNESDAY POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC), FOLLOWING INTERIM ANALYSIS OF STUDY AB12005 IN THE FIRST-LINE TREATMENT OF PANCREATIC CANCER.STUDY AB12005 IS INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 CONFIRMATORY STUDY OF MASITINIB IN FIRST-LINE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER PATIENTS WITH PAIN AT BASELINE OR TAKING OPIOIDS.PROBABILITY OF SUCCESS OF STUDY AB12005 IS ABOVE 80% IN THE SELECTED SUB-POPULATION.CO EXPECTS TO REPORT THE FINAL RESULTS FROM STUDY AB12005 IN 2020.  Full Article

AB Science Announces Lifting Of ANSM Clinical Hold
Tuesday, 28 May 2019 12:05pm EDT 

May 28 (Reuters) - AB SCIENCE SA ::AB SCIENCE ANNOUNCES THE LIFTING OF THE ANSM CLINICAL HOLD.  Full Article

AB Science FY Operating Loss Stable At 28.9 Million Euros
Tuesday, 30 Apr 2019 12:16pm EDT 

April 30 (Reuters) - AB SCIENCE SA ::AB SCIENCE REPORTS TODAY ITS ANNUAL FINANCIALS AS OF 31 DECEMBER 2018 AND PROVIDES AN UPDATE ON ITS ACTIVITIES.CASH POSITION OF 11.6MEUR AS OF 31 DECEMBER 2018, PLUS 5.7MEUR OF 2018 TAX CREDIT.NET LOSS OF 26.1M€ FOR THE YEAR 2018.FY OPERATING LOSS EUR 28.9 MILLION VERSUS LOSS OF EUR 28.4 MILLION YEAR AGO.FY NET REVENUES EUR 1.7 MILLION VERSUS EUR 1.7 MILLION YEAR AGO.  Full Article

Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size
Thursday, 4 Jan 2018 11:47am EST 

Jan 4 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE.‍FINAL RESULTS OF STUDY ARE EXPECTED IN Q2 2019​.‍IDMC DID NOT REPORT ANY SAFETY CONCERN WITH MASITINIB IN STUDY POPULATION​.  Full Article

AB Science net loss narrows to 13.5 million euros
Thursday, 31 Aug 2017 12:02pm EDT 

Aug 31 (Reuters) - AB SCIENCE SA ::NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR ).CASH POSITION OF 49.3MEUR AS OF 30 JUNE 2017, PLUS 6.9MEUR OF 2016 TAX CREDIT TO BE REIMBURSED BY PUBLIC FINANCE DEPARTMENT.PHASE 2/3 STUDY AB10015 OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) MET ITS PRE-SPECIFIED PRIMARY ENDPOINT, WHICH CONFIRMS INTERIM ANALYSIS.COMPANY TURNOVER AMOUNTS TO 842 K€ FOR THE FIRST HALF OF 2017, AS COMPARED WITH 772 K€ ONE YEAR EARLIER.OPERATING LOSS AS AT 30 JUNE 2017 AMOUNTED TO 13,709 K€ AS COMPARED WITH 16,099 K€ AS AT 30 JUNE 2016.  Full Article

AB Science announces issuance of a new european patent
Wednesday, 12 Jul 2017 11:56am EDT 

July 12 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS.ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING USE OF MASITINIB IN PANCREATIC CANCER PATIENTS WITH PAIN UNTIL 2033.RECRUITMENT TARGET OF 330 PATIENTS IN ONGOING CONFIRMATORY PHASE 3 STUDY HAS JUST BEEN REACHED.  Full Article

BRIEF-AB Science: Positive Recommendation Of IDMC Following Interim Analysis Of Study AB12005

* ANNOUNCED ON WEDNESDAY POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC), FOLLOWING INTERIM ANALYSIS OF STUDY AB12005 IN THE FIRST-LINE TREATMENT OF PANCREATIC CANCER